Literature DB >> 22536001

Hematopoietic precursor cells isolated from patients on long-term suppressive HIV therapy did not contain HIV-1 DNA.

Lina Josefsson1, Susanne Eriksson, Elizabeth Sinclair, Terence Ho, Maudi Killian, Lorrie Epling, Wei Shao, Bradley Lewis, Peter Bacchetti, Lisa Loeb, Jeff Custer, Lauren Poole, Frederick M Hecht, Sarah Palmer.   

Abstract

BACKGROUND: We address the key emerging question of whether Lin(-)/CD34(+) hematopoietic precursor cells (HPCs) represent an important latent reservoir of human immunodeficiency virus type 1 (HIV-1) during long-term suppressive therapy.
METHODS: To estimate the frequency of HIV-1 infection in bone marrow, we sorted Lin(-)/CD34(+) HPCs and 3 other cell types (Lin(-)/CD34(-), Lin(-)/CD4(+), and Lin(+)/CD4(+)) from 8 patients who had undetectable viral loads for 3-12 years. Using a single-proviral sequencing method, we extracted, amplified, and sequenced multiple single HIV-1 DNA molecules from these cells and memory CD4(+) T cells from contemporaneous peripheral blood samples.
RESULTS: We analyzed 100,000-870,000 bone marrow Lin(-)/CD34(+) HPCs from the 8 patients and found no HIV-1 DNA. We did isolate HIV-1 DNA from their bone marrow Lin(+)/CD4(+) cells that was genetically similar to HIV-1 DNA from lymphoid cells located in the peripheral blood, indicating an exchange of infected cells between these compartments.
CONCLUSIONS: The absence of infected HPCs provides strong evidence that the HIV-1 infection frequency of Lin(-)/CD34(+) HPCs from bone marrow, if it occurred, was <.003% (highest upper 95% confidence interval) in all 8 patients. These results strongly suggest that Lin(-)/CD34(+) HPCs in bone marrow are not a source of persistent HIV-1 in patients on long-term suppressive therapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22536001      PMCID: PMC3415927          DOI: 10.1093/infdis/jis301

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  14 in total

1.  Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells.

Authors:  Justin R Bailey; Ahmad R Sedaghat; Tara Kieffer; Timothy Brennan; Patricia K Lee; Megan Wind-Rotolo; Christine M Haggerty; Ashrit R Kamireddi; Yi Liu; Jessica Lee; Deborah Persaud; Joel E Gallant; Joseph Cofrancesco; Thomas C Quinn; Claus O Wilke; Stuart C Ray; Janet D Siliciano; Richard E Nettles; Robert F Siliciano
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

2.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.

Authors:  D Finzi; M Hermankova; T Pierson; L M Carruth; C Buck; R E Chaisson; T C Quinn; K Chadwick; J Margolick; R Brookmeyer; J Gallant; M Markowitz; D D Ho; D D Richman; R F Siliciano
Journal:  Science       Date:  1997-11-14       Impact factor: 47.728

3.  Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.

Authors:  L Zhang; B Ramratnam; K Tenner-Racz; Y He; M Vesanen; S Lewin; A Talal; P Racz; A S Perelson; B T Korber; M Markowitz; D D Ho
Journal:  N Engl J Med       Date:  1999-05-27       Impact factor: 91.245

4.  Few infected CD4+ T cells but a high proportion of replication-competent provirus copies in asymptomatic human immunodeficiency virus type 1 infection.

Authors:  J E Brinchmann; J Albert; F Vartdal
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

5.  Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis.

Authors:  Sarah Palmer; Mary Kearney; Frank Maldarelli; Elias K Halvas; Christian J Bixby; Holly Bazmi; Diane Rock; Judith Falloon; Richard T Davey; Robin L Dewar; Julia A Metcalf; Scott Hammer; John W Mellors; John M Coffin
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

6.  Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine.

Authors:  Diane V Havlir; Kersten K Koelsch; Matthew C Strain; Nicolas Margot; Biao Lu; Caroline C Ignacio; Michael D Miller; Joseph K Wong
Journal:  J Infect Dis       Date:  2005-02-28       Impact factor: 5.226

Review 7.  Eradication of HIV: current challenges and new directions.

Authors:  Matthew D Marsden; Jerome A Zack
Journal:  J Antimicrob Chemother       Date:  2008-11-04       Impact factor: 5.790

8.  Infection of hematopoietic progenitor cells by HIV-1 subtype C, and its association with anemia in southern Africa.

Authors:  Andrew D Redd; Ava Avalos; Max Essex
Journal:  Blood       Date:  2007-08-10       Impact factor: 22.113

9.  Use of real-time PCR and molecular beacons to detect virus replication in human immunodeficiency virus type 1-infected individuals on prolonged effective antiretroviral therapy.

Authors:  S R Lewin; M Vesanen; L Kostrikis; A Hurley; M Duran; L Zhang; D D Ho; M Markowitz
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

10.  ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia.

Authors:  Frank Maldarelli; Sarah Palmer; Martin S King; Ann Wiegand; Michael A Polis; JoAnn Mican; Joseph A Kovacs; Richard T Davey; Diane Rock-Kress; Robin Dewar; Shuying Liu; Julia A Metcalf; Catherine Rehm; Scott C Brun; George J Hanna; Dale J Kempf; John M Coffin; John W Mellors
Journal:  PLoS Pathog       Date:  2007-04       Impact factor: 6.823

View more
  51 in total

1.  Hematopoietic cell transplantation and HIV cure: where we are and what next?

Authors:  Shimian Zou; Simone Glynn; Daniel Kuritzkes; Monica Shah; Nakela Cook; Nancy Berliner
Journal:  Blood       Date:  2013-09-05       Impact factor: 22.113

Review 2.  HIV-1 transcription and latency: an update.

Authors:  Carine Van Lint; Sophie Bouchat; Alessandro Marcello
Journal:  Retrovirology       Date:  2013-06-26       Impact factor: 4.602

Review 3.  Effects of human immunodeficiency virus on the erythrocyte and megakaryocyte lineages.

Authors:  Davide Gibellini; Alberto Clò; Silvia Morini; Anna Miserocchi; Cristina Ponti; Maria Carla Re
Journal:  World J Virol       Date:  2013-05-12

Review 4.  Potential implication of residual viremia in patients on effective antiretroviral therapy.

Authors:  Gautam K Sahu
Journal:  AIDS Res Hum Retroviruses       Date:  2015-01       Impact factor: 2.205

Review 5.  Underlying mechanisms of HIV-1 latency.

Authors:  Bizhan Romani; Elham Allahbakhshi
Journal:  Virus Genes       Date:  2017-03-03       Impact factor: 2.332

Review 6.  Current Strategies for Elimination of HIV-1 Latent Reservoirs Using Chemical Compounds Targeting Host and Viral Factors.

Authors:  Maxime J Jean; Guillaume Fiches; Tsuyoshi Hayashi; Jian Zhu
Journal:  AIDS Res Hum Retroviruses       Date:  2018-12-12       Impact factor: 2.205

Review 7.  Developing strategies for HIV-1 eradication.

Authors:  Christine M Durand; Joel N Blankson; Robert F Siliciano
Journal:  Trends Immunol       Date:  2012-08-03       Impact factor: 16.687

8.  CD133+ hematopoietic progenitor cells harbor HIV genomes in a subset of optimally treated people with long-term viral suppression.

Authors:  Lucy A McNamara; Adewunmi Onafuwa-Nuga; Nadia T Sebastian; James Riddell; Dale Bixby; Kathleen L Collins
Journal:  J Infect Dis       Date:  2013-04-03       Impact factor: 5.226

9.  Hematopoietic stem cells and HIV infection.

Authors:  Matthew Pace; Una O'Doherty
Journal:  J Infect Dis       Date:  2013-04-03       Impact factor: 5.226

10.  Preferential susceptibility of Th9 and Th2 CD4+ T cells to X4-tropic HIV-1 infection.

Authors:  Nina Orlova-Fink; Fatema Z Chowdhury; Xiaoming Sun; Sean Harrington; Eric S Rosenberg; Xu G Yu; Mathias Lichterfeld
Journal:  AIDS       Date:  2017-10-23       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.